These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 32670370)

  • 1. Prognostic Significance of Tumor Tissue NeuGcGM3 Ganglioside Expression in Patients Receiving Racotumomab Immunotherapy.
    Uskent N; Ayla S; Molinas Mandel N; Ozkan M; Teomete M; Baloglu H; Aydıncer C; Yergok H; Dogan E; Berk B; Yazar A
    J Oncol; 2020; 2020():1360431. PubMed ID: 32670370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-ganglioside antibodies induced in chickens by an alum-adsorbed anti-idiotype antibody targeting NeuGcGM3.
    Guthmann MD; Venier C; Toledo D; Segatori VI; Alonso DF; Fainboim L; Vázquez AM; Ostrowski H
    Front Immunol; 2012; 3():422. PubMed ID: 23335925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-dependent cell-mediated cytotoxicity induced by active immunotherapy based on racotumomab in non-small cell lung cancer patients.
    Segatori VI; Cuello HA; Gulino CA; Albertó M; Venier C; Guthmann MD; Demarco IA; Alonso DF; Gabri MR
    Cancer Immunol Immunother; 2018 Aug; 67(8):1285-1296. PubMed ID: 29936534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase I Study of the Anti-Idiotype Vaccine Racotumomab in Neuroblastoma and Other Pediatric Refractory Malignancies.
    Cacciavillano W; Sampor C; Venier C; Gabri MR; de Dávila MT; Galluzzo ML; Guthmann MD; Fainboim L; Alonso DF; Chantada GL
    Pediatr Blood Cancer; 2015 Dec; 62(12):2120-4. PubMed ID: 26154941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients.
    Alfonso S; Valdés-Zayas A; Santiesteban ER; Flores YI; Areces F; Hernández M; Viada CE; Mendoza IC; Guerra PP; García E; Ortiz RA; de la Torre AV; Cepeda M; Pérez K; Chong E; Hernández AM; Toledo D; González Z; Mazorra Z; Crombet T; Pérez R; Vázquez AM; Macías AE
    Clin Cancer Res; 2014 Jul; 20(14):3660-71. PubMed ID: 24788102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Racotumomab - a novel anti-idiotype monoclonal antibody vaccine for the treatment of cancer.
    Gajdosik Z
    Drugs Today (Barc); 2014 Apr; 50(4):301-7. PubMed ID: 24918647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant expression of N-glycolyl GM3 ganglioside is associated with the aggressive biological behavior of human sarcomas.
    Pilco-Janeta D; De la Cruz Puebla M; Soriano J; Osorio M; Caballero I; Pérez AC; Savon L; Cremades N; Blanco R; Carr A
    BMC Cancer; 2019 Jun; 19(1):556. PubMed ID: 31182063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical evaluation of racotumomab, an anti-idiotype monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer.
    Segatori VI; Vazquez AM; Gomez DE; Gabri MR; Alonso DF
    Front Oncol; 2012; 2():160. PubMed ID: 23162791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides - preclinical and clinical data.
    Vázquez AM; Hernández AM; Macías A; Montero E; Gómez DE; Alonso DF; Gabri MR; Gómez RE
    Front Oncol; 2012; 2():150. PubMed ID: 23110257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune response to racotumomab in a child with relapsed neuroblastoma.
    Sampor C; Guthmann MD; Scursoni A; Cacciavillano W; Torbidoni A; Galluzzo L; Camarero S; Lopez J; de Dávila MT; Fainboim L; Chantada GL
    Front Oncol; 2012; 2():195. PubMed ID: 23267436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Significance of N-Glycolyl GM3 Ganglioside Expression in Non-Small Cell Lung Carcinoma Patients: New Evidences.
    Blanco R; Domínguez E; Morales O; Blanco D; Martínez D; Rengifo CE; Viada C; Cedeño M; Rengifo E; Carr A
    Patholog Res Int; 2015; 2015():132326. PubMed ID: 26634172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Racotumomab in Non-Small Cell Lung Cancer as Maintenance and Second-Line Treatment.
    Cáceres-Lavernia HH; Nenínger-Vinageras E; Varona-Rodríguez LM; Olivares-Romero YA; Sánchez-Rojas I; Mazorra-Herrera Z; Basanta-Bergolla D; Duvergel-Calderín D; Torres-Cuevas BL; Castillo-Carrillo C
    MEDICC Rev; 2021; 23(3-4):21-28. PubMed ID: 34516533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-Glycolyl GM3 ganglioside immunoexpression in oral mucosal melanomas of Chinese.
    Zhong Y; Wu Y; Li C; Tang J; Wang X; Ren G; Carr A; Pérez R; Guo W
    Oral Dis; 2012 Nov; 18(8):741-7. PubMed ID: 22574836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Racotumomab for treating lung cancer and pediatric refractory malignancies.
    Gabri MR; Cacciavillano W; Chantada GL; Alonso DF
    Expert Opin Biol Ther; 2016; 16(4):573-8. PubMed ID: 26903265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Racotumomab-alum vaccine for the treatment of non-small-cell lung cancer.
    Hernández AM; Vázquez AM
    Expert Rev Vaccines; 2015 Jan; 14(1):9-20. PubMed ID: 25420897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoreactivity of the 14F7 Mab Raised against N-Glycolyl GM3 Ganglioside in Epithelial Malignant Tumors from Digestive System.
    Blanco R; Rengifo E; Cedeño M; Rengifo CE; Alonso DF; Carr A
    ISRN Gastroenterol; 2011; 2011():645641. PubMed ID: 21991524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoreactivity of the 14F7 Mab Raised against N-Glycolyl GM3 Ganglioside in Primary Lymphoid Tumors and Lymph Node Metastasis.
    Blanco R; Blanco D; Quintana Y; Escobar X; Rengifo CE; Osorio M; Gutiérrez Z; Lamadrid J; Cedeño M; Frómeta M; Carr A; Rengifo E
    Patholog Res Int; 2013; 2013():920972. PubMed ID: 24381785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody.
    Hernández AM; Toledo D; Martínez D; Griñán T; Brito V; Macías A; Alfonso S; Rondón T; Suárez E; Vázquez AM; Pérez R
    J Immunol; 2008 Nov; 181(9):6625-34. PubMed ID: 18941253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequent co-expression of EGFR and NeuGcGM3 ganglioside in cancer: it's potential therapeutic implications.
    Palomo AG; Santana RB; Pérez XE; Santana DB; Gabri MR; Monzon KL; Pérez AC
    Clin Exp Metastasis; 2016 Oct; 33(7):717-25. PubMed ID: 27449755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunologic Response Elicited in Breast Cancer Patients Receiving a NeuGcGM3-based Vaccine as Adjuvant Therapy.
    Valdes-Zayas A; Gonzalez Z; Mulens V; Vega AM; Perez K; Lorenzo-Luaces P; Rubio MC; Estevez A; Curbelo I; Fernandez LE; Crombet T; Mazorra Z
    J Immunother; 2017 Oct; 40(8):289-301. PubMed ID: 28604556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.